Cellaion SA

Industry · 7 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF) Acute on Chronic Liver Failure	Phase 2	2020-01-21
Completed	Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients NASH - Nonalcoholic Steatohepatitis	Phase 1 / Phase 2	2019-04-09
Terminated	HepaStem Long-Term Safety Registry Urea Cycle Disorder, Crigler-Najjar Syndrome, Acute on Chronic Liver Failure	—	2018-04-04
Completed	Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF Acute-On-Chronic Liver Failure	Phase 2	2016-12-01
Completed	Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002) Urea Cycle Disorders	Phase 2	2014-10-01
Completed	Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001) Urea Cycle Disorders, Crigler Najjar Syndrome	—	2013-03-01
Completed	Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Urea Cycle Disorders, Crigler Najjar Syndrome	Phase 1 / Phase 2	2012-03-01